ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED

Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >

2 Signals to Watch Before Buying SAVA Stock ↗

October 05, 2022

SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play.

Via InvestorPlace

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗

September 28, 2022

Via Benzinga

Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results ↗

September 28, 2022

Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring.

Via InvestorPlace

Why Is Acumen (ABOS) Stock Up 95% Today? ↗

September 28, 2022

Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company.

Via InvestorPlace

This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval ↗

September 28, 2022

Via Benzinga

Why Is Biogen (BIIB) Stock Up 40% Today? ↗

September 28, 2022

Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors.

Via InvestorPlace

Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal ↗

August 03, 2022

Via Benzinga

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact ↗

March 15, 2022

Via Benzinga

Why Acumen Pharmaceuticals Stock Is Soaring Today ↗

September 28, 2022

Acumen Pharmaceuticals Inc (NASDAQ: ABOS) shares are trading higher Wednesday after Biogen Inc (NASDAQ: BIIB) and Eisai Co (Pink:

Via Benzinga

Why Is Cassava Sciences (SAVA) Stock Heating Up Today? ↗

September 28, 2022

SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target.

Via InvestorPlace

Is iPhone Demand Really Slowing Down?, Lyft Freezes Hiring, Biogen's New Drug Slows Alzheimer's Progression: Top Financial Media Stories Wednesday, Sept. 28 ↗

September 28, 2022

Bloomberg

Via Benzinga

What In The World Is Going On With Biogen (BIIB) Shares? ↗

September 28, 2022

Biogen Inc (NASDAQ: BIIB) shares are trading higher by 42.62% to $282.08 during Wednesday's pre-market session after the company and Eisai Co.

Via Benzinga

Why Cassava Sciences Shares Are Soaring Higher ↗

September 28, 2022

Cassava Sciences Inc (NASDAQ: SAVA) shares are trading higher by 7.15 to $49.48 during Wednesday's pre-market session after Biogen Inc (NASDAQ: BIIB) and Eisai Co.

Via Benzinga

Why Biogen Stock Is Up 40% Today ↗

September 28, 2022

Biogen, Inc. (NASDAQ: BIIB) shares are soaring over 43% to their highest level in about a year in premarket trading Wednesday.

Via Benzinga

2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data ↗

September 28, 2022

Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd.

Via Benzinga

US Stock Futures Down Ahead Of Fed Speakers, Economic Data ↗

September 28, 2022

Pre-open movers U.S. stock futures traded lower in early pre-market trade on Wednesday after closing mostly lower on Tuesday. The S&P 500 index dropped deeper into a bear market after hitting a fresh...

Via Benzinga

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock ↗

September 28, 2022

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

Via Benzinga

Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer ↗

September 12, 2022

Via Benzinga

Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate ↗

August 25, 2022

Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗

July 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment ↗

May 10, 2022

Eisai finished submitting its application for lecanemab, another anti-amyloid drug.

Via Investor's Business Daily

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug ↗

May 10, 2022

Via Benzinga

The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study ↗

April 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab ↗

March 22, 2022

In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have

Via Benzinga

FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer ↗

March 22, 2022

The

Via Benzinga

News-Filled Day ↗

March 15, 2022

The price of oil fell to below $100/oz on the prospect of lower demand from the PRC.

Via Talk Markets

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Hopes For A Peace Accord ↗

March 14, 2022

The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.